Insulin-like growth factors (IGFs) in blood form two complexes with specific binding proteins (BPs): a large, growth hormone (GH)-dependent complex with restricted capillary permeability, and a smaller complex, inversely related to GH, with high turnover of its IGF pool and free capillary permeability. The distribution of BPs and of IGFs I and II between these complexes was studied in sera from healthy adults treated with IGF I or/and GH and from patients with extrapancreatic tumor hypoglycemia. Like GH, IGF I administration raises IGF I and two glycosylation variants of IGFBP-3 in the large complex, but unlike GH drastically reduces IGF II. During IGF I infusion, IGFBP-3 appears in the small complex whose IGFBP-2 and IGF I increase three-to fivefold and fivefold, respectively. GH treatment, associated with elevated insulin levels, suppresses IGFBP-2 and inhibits its increase owing to infused IGF I. The small complex of tumor sera contains increased amounts of IGFBP-2 and -3, and two-to threefold elevated IGF IL Conclusions: low GH and/or insulin during IGF I infusion and in extrapancreatic tumor hypoglycemia enhance expression of IGFBP-2 and favor partition of IGFBP-3 into the small complex. Free capillary passage and high turnover of its increased IGF I or II pools may contribute to compensate for suppressed insulin secretion during IGF I infusion or to development of tumor hypoglycemia. (J. Clin. Invest. 1990. 86:952-961.) Key words: IGF binding proteins-IGF I treatment * extrapancreatic tumor hypoglycemia Introduction Insulin-like growth factors (IGFs)' are synthesized and released by many tissues and cell types (1, 2). The liver contributes most of the IGFs in the circulation (1, 3). IGFs are always found in association with specific high-affinity binding proteins (2). As is true for IGFs, the highest concentrations of IGF
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Insulin-like growth factors (IGFs)' are synthesized and released by many tissues and cell types (1, 2). The liver contributes most of the IGFs in the circulation (1, 3) . IGFs are always found in association with specific high-affinity binding proteins (2). As is true for IGFs, the highest concentrations of IGF lin-like growth factor; IGFBP, IGF binding protein; rh, recombinant human.
binding proteins (IGFBPs) are found in blood. However, they have also been detected in interstitial and cerebrospinal fluid (2, 4, 5) and in media of cultured cells or organ explants (2, [6] [7] [8] .
The physiological role of the IGFBPs is not yet completely unraveled. They prolong the half-life of the IGFs in the circulation (9, 10) and protect the organism against acute insulinlike effects of the IGFs (10, 11) . In the interstitial fluid they may modulate the bioavailability of locally secreted IGFs to IGF target cells (7, 8, (12) (13) (14) . Finally, they appear to be involved in specific IGF targeting (11, 15) .
Native adult human serum contains two IGFBP complexes with respective apparent molecular masses of 160-1802 and 50-55 kD (16) . The large complex is growth hormone (GH)-dependent (17, 18) . It consists of glycosylated IGF binding subunits, IGF itself, and a glycosylated acid-labile protein which binds only IGF complexed with IGF binding subunits (19, 20) . The small complex is inversely related to the GH status ( 17) . The chemical nature of its constituents has not yet been completely elucidated.
Infusion of recombinant human (rh)IGF I into normal adults inhibits insulin and GH secretion, suppresses serum IGF II levels, and increases renal function (21) . In this context, we looked for possible changes of IGFBPs and discovered that rhIGF I "induces" a specific IGFBP, which is the predominant form in human fetal sera and in sera of patients with Laron dwarfism and with extrapancreatic tumor hypoglycemia.
Methods

Subjects and experimental protocol
Serum samples were from the same two subjects as in the study of Guler et al. (21) . The experimental protocol and the infusion regime have been described in detail. rhIGF I (a generous gift from Dr. W. J. Rutter, Chiron Corp., Emeryville, CA and Dr. J. Nfiesch, Ciba-Geigy AG, Basel) was infused s.c. at a rate of 20 ,ug/kg body weight per h for 6 d. RhGH (Norditropin, Nordisk Gentofte, Denmark) was injected at a dose of 2 X 3 mg/d s.c. for 6 d. On days 5 and 6, rhIGF I was infused together with GH treatment. Fetal sera were obtained from infants delivered between 27 and 43 wk of gestation. Sera from patients with extrapancreatic tumor hypoglycemia were obtained from referring physicians from several European countries. All sera were stored at -20'C until used for analysis.
bated for 24 h at 4VC with I25-labeled IGF I or II (4-6 X I05 cpm, 2-3 ng) and passed over a Sephadex G-200 column (2 X 70 cm, pumping rate 13 ml/h), calibrated with a gel filtration calibration kit (Pharmacia, Uppsala, Sweden). The radioactivity ofthe fractions was measured in a -y-counter (Berthold, Wildbad, FRG). Nonspecific binding was assessed in the presence of excess unlabeled IGF (1 1). Radiochromatographic patterns of human sera are identical with 1251I-IGF I or 12511 IGF II (J. Zapf, unpublished observation).
Fractionation ofsera on Sephadex G-200. 1 -ml serum samples were passed over the same column as used for radiochromatography and eluted under identical conditions. The e-globulin and albumin peaks were used for internal calibration during successive runs. Fractions corresponding to an apparent molecular mass range of 120-300 kD (pool I), 50-120 kD (pool II), and 21-50 kD (pool III) were pooled, dialyzed against 0.1 M NH4HCO3, lyophilized, and dissolved in 1 ml (pools I and II) or 0.5 ml (pool III) of distilled water for ligand blot analysis (see below) and for determination of IGF I and II by radioimmunoassay (RIA) (22) . Before the RIA, carrier proteins were removed by Sep-Pak chromatography according to the instructions of the supplier (Waters Associates, Milford, MA).
Fractionation ofsera on concanavalin A (Con A) Sepharose. 0.1 ml ofserum diluted with 0.1 ml 0.05 M sodium phosphate buffer, pH 7.4, containing 0.2 M NaCI and 0.02% NaN3 (starting buffer) was passed over 2 ml Con A Sepharose columns as described (1 1 Marker, Amersham International, Amersham, UK). Electroblotting on nitrocellulose was performed in a transblot cell (Bio-Rad Laboratories, Richmond, CA) for 2 h at 0.6-1.0 A. The air-dried nitrocellulose sheets were processed as described (I 1, 23) except that 1% fish gelatine (LB solution, Inotech, Wohlen, Switzerland) was used instead ofalbumin to block nonspecific binding sites. Each sheet was incubated for 6 h at room temperature in a sealed plastic bag with 4 X 106 cpm of 125I-labeled IGF I or 11 (11) , washed extensively (11, 23) , air-dried, and exposed for 8-48 h at -70°C to X-ray film (X-Omat AR) in a Kodak X-Omatic cassette (Eastman Kodak Co., Rochester, NY).
For quantitative analysis, the nitrocellulose membrane was fitted on the autoradiogram on a fluorescent screen, and the bands were marked with a pencil on the nitrocellulose membrane. Marked bands were cut out and counted in a y-counter. Corresponding Fig. 2 b) ; (c) two other bands appear at 31 and 33 kD (Fig. 2 a) . All of these changes are reversible. The 36-kD signal decreases with a halflife of 30 h (Fig. 2, b and c) .
The intensity of the 42/45-kD doublet increases 2 d after GH administration (Fig. 3) . IGF I further enhances this increase (Fig. 3, a and b) . However, in contrast to IGF I, GH reduces the 36-kD signal. This is particularly obvious when GH and rhIGF I are administered together (Fig. 3 a, last two lanes, and Fig. 3 16 and Fig. 4 ). During IGF I infusion the large molecular mass peak decreases, whereas the 50-55-kD peak increases and shifts to 60-65 kD. In contrast, GH administration causes an increase of the 160-180-kD peak and a concomitant decrease and shift of the 50-55-kD peak (Fig. 4) . Serum fractions were pooled as shown in Fig. 4 (pools I, II, and III) and the concentrated pools were subjected to ligand blot analysis (Fig.  5) . Pool I, which contains the native large molecular mass IGFBP complex, yields the 42/45-kD doublet and the 3 1-kD band. The latter is visible only after prolonged exposure times (not shown). The intensity of the doublet in pool I, in particular the intensity of the 42-kD band, is increased during IGF I or GH administration, and further enhanced by the combination ofthe two hormones (Figs. 2, a and b, and 3, a and b). The increase of the doublet signal in pool I during IGF I infusion contrasts with the decrease of '251-IGF I binding to the native 160-180-kD peak (Fig. 4) . Apparently, the availability of IGF binding sites is reduced due to increased occupancy by exogenous IGF I (see Table I ), which may not be readily exchangeable.
The 36-kD band elutes in pool II within an apparent molecular mass range of 50-120 kD (Figs. 4 and 5). During IGF I infusion, but not during GH treatment, the 42/45-kD doublet appears also in pool II (Fig. 5) during IGF I infusion is detected mainly in pool III together with the 28-30 and the 24-kD band, when more concentrated aliquots are electrophoresed and exposure times are increased (not shown). The increase of the amplil -de of the radioactive 60-65-kD peak during IGF I infusion (Fig. 4) is reflected by the increased intensity of the 36-kD band and the appearance of the 42/45-kD doublet in this molecular mass range. Similarly, the decrease of this peak during GH administration is reflected by the decrease of the 36-kD band (Fig. 3 b) .
The above results show that the 42/45-kD IGF binding subunits are mainly constituents of the 160-180-kD native carrier protein complex, whereas the 36-kD band represents the predominant constituent of the smaller complex.
Fractionation of sera on Con A-Sepharose confirms that the 42/45-kD doublet and the 36-kD band are different entities (Fig. 6 a) : the 36-kD protein appears in the flowthrough, whereas the 42/45-kD doublet is adsorbed and eluted with 0.25 M methylmannose. Digestion of the 42/45-kD doublet with N-glycanase yields a single band at 37 kD. The nonadsorbed 36-and 33-kD bands are not digestable with N-glycanase (Fig. 6 b) . In agreement with the results of Figs. 2 and 3 , the intensity of the 36-kD band in the flow-through is significantly increased during IGF I infusion, whereas it is diminished during GH treatment (Fig. 6 a) . Fig. 4 and the fractions were pooled according to the molecular mass ranges indicated by I, II, and III in Fig. 4 . The pools were extensively dialyzed against 0. M NH4HCO3, lyophilized, and redissolved in ml (pools I and II) or 0.5 ml (pool III) of distilled water for ligand blot analysis and for IGF I and II determination by RIA (22). 5, 7, and 25 1Al of each pool were electrophoresed and processed as described in Methods. Exposure time was 22 h. NHS, normal human serum.
The major portion of IGF I and IGF II elutes in pool I, i.e., together with the large molecular mass native carrier complex (Table I) (Fig. 7) and is, therefore, not associated with the large complex. Consistent with this finding and in contrast to normal serum, 65-70% of the total IGF is recovered in pools II and III (Table II) , whereas in normal serum these pools contain only 21-27% of the total IGF (Tables I  and II (28) as also reported by Baxter et al. (25) for their 47/53-kD proteins. This sequence is identical to the NH2 terminus of IGFBP-3 (20, 25, 29) . The NH2 terminus of the purified 31-kD protein, which appears together with the 42/45-kD doublet in pool I during IGF I infusion, is the same as that of IGFBP-3 (28) . Presumably it is a degradation product of BP-3 lacking the COOH terminus. A corresponding protein has been isolated from rat serum (1 1).
The 36-kD band, the major constituent ofthe small carrier complex. The 36-kD ligand blot band represents a nonglycosylated protein (Fig. 6 b) . Hardouin et al. (24) report an apparent molecular mass of 34-kD. It does not cross-react with antiserum to human IGFBP-1 nor to IGFBP-3 (30). On Sephadex G-200 gel permeation chromatography, it elutes between 50 and 120-kD (Figs. 4 and 5) . It may, therefore, exist as a dimer in native serum. On ligand blots the purified protein yields an additional weak radioactive signal at 70-kD (J. Zapf, unpublished observation). The 36-kD protein is the predominant IGFBP in human fetal sera (Fig. 1) and in sera from patients with Laron dwarfism (Fig. 1 and reference 30) , and it is a major IGFBP in sera from patients with extrapancreatic tumor hypoglycemia (Figs. 1 and 7) . We have purified the 36-kD Figure 7 . '251-IGF II ligand blot analysis of pooled fractions obtained by neutral Sephadex G-200 gel permeation chromatography of sera from normal adults (pool) and from three patients with extrapancreatic tumor hypoglycemia. 1 ml of serum was gel-filtered on Sephadex G-200 and fractions were pooled (pools I, II, and III) as described in Fig. 5 according to the molecular mass ranges indicated in the radiochromatographic pattern of Fig. 4 . Pools were dialyzed against 0.1 M NH4HCO3, lyophilized, and redissolved in 1 ml (pools I and II) or 0.5 ml (pool III) of distilled water. 10 Al of each pool was electrophoresed and processed as described in Methods (21) and would thus confirm findings in the rat (11) suggesting that the synthesis of the acid-labile subunit is not an IGF I-mediated, but a direct effect of GH. Although some "trailing" of the large complex into pool II during gel filtration cannot be excluded, it certainly cannot account for the finding that, in contrast to normal serum, a large portion of 42/45-kD IGF binding subunits is found in pool II of sera from patients with extrapancreatic tumor hypoglycemia.
The 33-kD protein representing the second prominent ligand blot band in fetal serum and in serum of Laron dwarfs (Fig. 1) is detected in normal adult serum only during IGF I infusion (Fig. 2, a and b) . It corresponds to the "slow" 30-kD band of Hardouin et al. (30) and cross-reacts with antibodies to amniotic fluid IGFBP (IGFBP-1) (30) .
Regulation ofthe 36-and 42/45-kD binding proteins: (IGFBP-2 and -3)
The "induction" ofthe 36-kD BP by IGF I infusion is striking. GH, which raised endogenous IGF I levels to a similar extent as infusion of rhIGF I (Table I) (11, 37) . Most likely it represents rat IGFBP-2. Expression of the mRNA encoding this protein is highly increased in livers of diabetic rats and suppressed by insulin treatment (38) . In agreement with these findings, physiological concentrations of insulin inhibit the release from rat hepatocytes in vitro of a 33/34-kD nonglycosylated IGFBP (39) and at the same time completely inhibit accumulation of IGFBP-2 mRNA (40). Treatment of hepatocytes with GH or physiological concentrations of IGF I does not affect the release of IGFBP-2 (40). Nor does GH or IGF I treatment of diabetic rats affect the 33/34-kD ligand blot band in the serum of these animals (11, 37) . However, we consider it very likely that in the human in vivo both insulin and GH regulate human IGFBP-2 by inhibiting its expression:
1. IGF I infusion suppresses insulin and GH secretion (21) , leading to increased expression of IGFBP-2.
2. GH treatment (21) or oversecretion of GH is accompanied by increased insulin secretion (41). When administered together with IGF I, GH suppresses the "induction" of IGFBP-2 by IGF I.
3. Low insulin levels are found in patients with Laron dwarfism, who are unresponsive to GH (42) , and in patients with extrapancreatic tumor hypoglycemia who have low serum GH levels (43, 44) . Consequently, IGFBP-2 is overexpressed in these patients. An increased intensity of a 34-kD band (corresponding to our 36-kD band) has been found in GH-deficient patients (23, 24, 30) who also have low insulin levels. In contrast, this band is less intense than normal in patients with acromegaly (24, 30) . Decreased responsiveness to GH may contribute to the increased expression of IGFBP-2 in the fetus.
The GH dependence ofthe large IGF carrier complex (Fig.  4) is well established (17, 18) . Consequently, the 42/45-kD IGF binding subunits (IGFBP-3) (Fig. 3, a and b , and references 24 and 30) and the acid-labile subunit (11, 26) are also under GH control. GH deficiency (24, 30) as well as decreased responsiveness (fetus) or unresponsiveness to GH (Laron dwarf) are accompanied by a reduction or lack of IGFIBP-3 (Fig. 1) . BP-3 increased during GH treatment after a lag period of 2 d (Fig. 3 b) , i.e., not before the endogenous IGF I had reached levels of 400-500 ng/ml (21) . On the other hand, rhIGF I itself caused an increase of BP-3 and further enhanced the increase of IGFBP-3 due to GH (Figs. 2 b and 3 b) . In contrast to GH, rhIGF I had already induced BP-3 after 12-24 h, but the induction was transient. BP-3 decreased again under the IGF I infusion (Fig. 2 b) despite elevated serum IGF I levels (21) . These results suggest that IGF I induces IGFBP-3 only in the presence of normal or elevated serum GH and insulin levels (at the beginning ofthe IGF I infusion or during GH and GH plus IGF I treatment), whereas decreased GH and insulin levels during the IGF I infusion (21) appear to counteract this IGF I effect.
A possible role ofIGFBP-2 in glucose homeostasis and in the development ofextrapancreatic tumor hypoglycemia
The increased IGFBP-2 levels during IGF I infusion and the concomitant increase of IGF I circulating with this protein as small carrier complex (pool II, Fig. 4 ) may affect glucose homeostasis: in contrast to the large IGF carrier complex, the small complex passes the capillary system (4) and thus carries increased amounts of rhIGF I into the interstitial space. The short half-life of IGF associated with the small complex (10, 45) indicates a high turnover of this IGF pool. This may further enhance the delivery of rhIGF I into the interstitial space. In addition, the lower affinity of IGFBP-2 for IGF I than for IGF II (24) globulin fraction (corresponding to our pool I). From this abnormal distribution of IGF II they concluded that its tissue accessibility is increased resulting in hypoglycemia. Our findings demonstrate that the 50-120-kD serum pool contains both increased amounts of IGFBP-2 and IGFBP-3 (Fig. 7) . The sequestration of IGFBP-3 into pool II indicates a relative lack of the acid-labile subunit which in normal serum occurs in threefold molar excess of IGF and IGFBP-3 (47). The concentration of IGF II circulating with the small carrier complex is two-to threefold higher than in healthy individuals (Table  II) . Thus, increased amounts ofIGF II may reach insulin target cells and elicit insulin-like effects like inhibition of lipolysis and increased glucose consumption. It is unknown whether or not, or in which form, IGF II inhibits or blocks hepatic glucose output. In contrast to other organs where the capillary system restricts the passage of the large IGF carrier complex (4, 48) , the fenestrated capillary endothelium of the liver does not form a diffusion barrier. The hepatocyte is "bathed" in serum and should, therefore, be also in contact with the large carrier complex. Obviously, the high amounts of IGF II bound to this complex in normal serum are not recognized in this form by the insulin receptor of the hepatocyte. Otherwise, a normal liver would be continuously exposed to a huge insulin-like potential. One could speculate, however, that IGF II reaching the hepatocyte in a different form, namely as the binary IGF-IGFBP-3 complex, might be able to block hepatic glucose output in the liver as is typical for extrapancreatic tumor hypoglycemia (49).
Our findings may contribute to smoothing the controversy between several groups of investigators on whether or not IGF II is responsible for extrapancreatic tumor hypoglycemia. Total IGF II levels have been found to be normal (22, 35, 36) or elevated in this disease (43, 44, 49 ). It appears, however, that it is not the total IGF II level which is important in the development of this type ofhypoglycemia, but the preferential association of increased amounts of IGF II with the small IGF carrier protein complex in which IGF has a high turnover rate (45) .
